COMMUNICATION
News & Press Release
Total 122
-
92Neurobiogen 'Clinical Phase 1 Termination'...Proposing a New Paradigm for the Treatment of Dementia
DATE : 2024-03-20
VIEW : 2640
-
91Neurobiogen "Confirms Safety in Phase 1 Clinical Trials for Native Obesity Drugs..."Look forward to
DATE : 2024-03-20
VIEW : 2635
-
90[Life magazine's great day] Modern people's chronic disease, obesity! How can I get out of this?
DATE : 2024-02-08
VIEW : 2638
-
89Neurobiogen "Innovation Cost If Phase 1 Clinical Success..."I'm in phase 2 next year".
DATE : 2023-12-15
VIEW : 2662
-
88CNR Research Applies for Phase 2 Pre-IND of Multi-Race Clinical Trials for Dementia/Obesity Treatmen
DATE : 2023-10-04
VIEW : 2654
-
87CNR Research "U.S. FDA Pre-IND Application for Dementia and Obesity Treatment Substances".
DATE : 2023-10-04
VIEW : 2663
-
86CNR Research Signs FDA Pre-IND Contract For Neurobiogen Dementia/Obesity Treatment.
DATE : 2023-10-04
VIEW : 2676
-
85CNR Research Signs U.S. FDA Pre-IND With NeuroBiogen.
DATE : 2023-10-04
VIEW : 2787
-
84CNR Research, Neurobiogen U.S. FDA Pre-IND Contract.
DATE : 2023-10-04
VIEW : 2686
-
83CNR Research Signs U.S. FDA Pre-IND Agreement With NeuroBiogen.
DATE : 2023-10-04
VIEW : 2734
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com
FAMILY SITE
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved